Survival Benefit of Lenvatinib Plus PD-1 Inhibitor with or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: a Multicenter Cohort Study

Overview

Journal Immunotargets Ther

Publisher Dove Medical Press

Specialty Allergy & Immunology

Date 2024 Sep 16

PMID 39280092

Authors

Murong Wang

Qunfang Zhou

Hui Li

Mingyu Liu

Ruixia Li

Wei Wang

Xiaohui Wang

Jinhua Huang

Feng Duan

Affiliations

Soon will be listed here.

Abstract

Purpose: The outcome between Lenvatinib plus programmed cell death protein-1 (PD-1) inhibitor and Lenvatinib in HCC beyond oligometastasis was unclear. In this multicenter, we compared the prognosis of Lenvatinib plus PD-1 inhibitor with Lenvatinib in HCC beyond oligometastasis.

Patients And Methods: A total of 296 patients from six institutions were included. The patients were divided into two groups: (a) concurrent Lenvatinib plus PD-1 inhibitor treatment (Len+PD-1 group) and (b) Lenvatinib monotherapy (Len group). The primary endpoint was overall survival (OS), the second endpoint was progression-free survival (PFS) and efficacy.

Results: The median OS was 20.1 ± 1.2 (17.7-22.5) months and 15.7 ± 1.5 (12.8-18.6) months in the Len+PD-1 and Len groups, respectively. The 12-, 24-, and 36-month OS rates were 79.1%, 39.4%, and 10.7% in the Len+PD-1 group, and 76.3%, 29.7%, and 0% in the Len group, respectively. The OS and PFS rates of the Len+PD-1 group were significantly longer compared with the Len group (hazard ratio [HR], 0.88; 95% confidence index [CI], 0.49-0.94; = 0.021) and (HR, 0.66; 95% CI, 0.50-0.87; = 0.003). A subgroup analysis revealed that OS (HR, 0.57; 95% CI, 0.36-0.90; = 0.016) was improved between the Len+PD-1 and Len groups with hepatic artery infusion chemotherapy (HAIC) treatment, whereas OS (HR, 1.11; 95% CI, 0.68-1.80; = 0.689) was similar between the Len and Len+PD-1 groups without HAIC.

Conclusion: Lenvatinib combined with PD-1 inhibitor significantly improves the survival of HCC beyond oligometastasis. For patients with HAIC, there was obviously significance between Len and Len+PD-1 groups.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Zhu H, Li H, Huang M, Yang W, Yin G, Zhong B . Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. 2023; 8(1):58. PMC: 9905571. DOI: 10.1038/s41392-022-01235-0. View

Cappuyns S, Corbett V, Yarchoan M, Finn R, Llovet J . Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review. JAMA Oncol. 2023; 10(3):395-404. PMC: 10837331. DOI: 10.1001/jamaoncol.2023.2677. View

Borde T, Nezami N, Laage Gaupp F, Savic L, Taddei T, Jaffe A . Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology. 2022; 304(1):228-237. PMC: 9270683. DOI: 10.1148/radiol.212426. View

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

Guan R, Zhang N, Deng M, Lin Y, Huang G, Fu Y . Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors. Int J Surg. 2024; 110(7):4062-4073. PMC: 11254277. DOI: 10.1097/JS9.0000000000001378. View

He M, Li Q, Zou R, Shen J, Fang W, Tan G . Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol. 2019; 5(7):953-960. PMC: 6512278. DOI: 10.1001/jamaoncol.2019.0250. View

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

Kudo M, Finn R, Cheng A, Zhu A, Ducreux M, Galle P . Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study. Liver Cancer. 2023; 12(5):479-493. PMC: 10601852. DOI: 10.1159/000529996. View

10.

Xia C, Dong X, Li H, Cao M, Sun D, He S . Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022; 135(5):584-590. PMC: 8920425. DOI: 10.1097/CM9.0000000000002108. View

11.

Zhang W, Zhang K, Liu C, Gao W, Si T, Zou Q . Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study. Front Immunol. 2023; 14:1127349. PMC: 10169627. DOI: 10.3389/fimmu.2023.1127349. View

12.

Qin S, Chan S, Gu S, Bai Y, Ren Z, Lin X . Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023; 402(10408):1133-1146. DOI: 10.1016/S0140-6736(23)00961-3. View

13.

Tong Y, Cai R, Li J, Chang D, Wang L, Cai W . Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability of treatment weighting analysis. Aliment Pharmacol Ther. 2022; 56(11-12):1602-1614. DOI: 10.1111/apt.17263. View

14.

Xin Y, Zhang X, Liu N, Peng G, Huang X, Cao X . Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma. Hepatol Int. 2023; 17(3):753-764. DOI: 10.1007/s12072-023-10502-3. View

15.

Long T, Yang Z, Zeng H, Wu W, Hu Z, Yang Z . Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2023; 10:1849-1859. PMC: 10596130. DOI: 10.2147/JHC.S436211. View

16.

Mei J, Li S, Li Q, Sun X, Lu L, Lin W . Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:167-176. PMC: 8007560. DOI: 10.2147/JHC.S298538. View

17.

Lima H, Endo Y, Alaimo L, Moazzam Z, Munir M, Shaikh C . Tumor Burden Score and Serum Alpha-fetoprotein Subclassify Intermediate-Stage Hepatocellular Carcinoma. J Gastrointest Surg. 2022; 26(12):2512-2521. DOI: 10.1007/s11605-022-05469-9. View

18.

Niu M, Yi M, Wu Y, Lyu L, He Q, Yang R . Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy. J Hematol Oncol. 2023; 16(1):94. PMC: 10423429. DOI: 10.1186/s13045-023-01487-5. View

19.

Lai Z, He M, Bu X, Xu Y, Huang Y, Wen D . Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. Eur J Cancer. 2022; 174:68-77. DOI: 10.1016/j.ejca.2022.07.005. View

20.

Zhu Y, Chen M, Xu D, Li T, Zhang Z, Li J . The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma. Cell Mol Immunol. 2022; 19(6):726-737. PMC: 9151669. DOI: 10.1038/s41423-022-00848-3. View